Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
Latest Media Releases
20/03/2019 10:11:00
Sydney, Australia, 20 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it had received and accepted the minutes of its Pre-Investigational New Drug (IND…
14/03/2019 09:23:00
First patient dosed in 68 patient Randomised Phase 2 HER-Vaxx cancer trial
Two Eastern European sites now actively recruiting
Approval imminent for trial sites in Hong Kong, Taiwan,…
04/03/2019 08:19:00
SYDNEY, Australia, 4 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on the KEY-Vaxx and B-Vaxx…
Latest News
Company News /
by Rachael Jones -
6 days ago
14 Mar 2019 - Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.
Company News /
by Anna Napoli -
2 months ago
07 Jan 2019 - Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.
Company Presentations /
by -
4 months ago
26 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell…
Interviews /
by Rachael Jones -
4 months ago
29 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong talks trial progress with the company's lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines …
Market Reports /
by Rachael Jones -
5 months ago
01 Oct 2018 - It's been a quiet day on the markets with the ASX closing lower. New Zealand software company Xero did well today, Nufarm shares were down. The Canadian dollar and Me…
Company News /
by Anna Napoli -
5 months ago
01 Oct 2018 - Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.
Company News /
by Rachael Jones -
5 months ago
21 Sep 2018 - Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx.
Company News /
by Anna Napoli -
6 months ago
11 Sep 2018 - Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recrui…
Market Reports /
by Jessica Amir -
9 months ago
08 Jun 2018 - Market Wrap. ASX20, ASX50, ASX100 and ASX200 reshuffled with Afterpay Touch (ASX:APT) & Kidman Resources (ASX:KDR) in ASX200. MMJ PhyoTech (ASX:MMJ) pleased Canada cl…
Interviews /
by Rachael Jones -
A year ago
09 March 2018 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks 1H18 and outlook, including progress with the company's lead HER-Vaxx cancer vaccine.
Company News /
by Kathy Skantzos -
A year ago
23 Nov 2017 - Immune-oncology company Imugene (ASX:IMU) raises $8.7 million through a $6.7 million institutional placement and a $2 million fully underwritten entitlement offer.
Company Presentations /
by -
A year ago
12 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong presents at the FNN Small Cap Investor Event, October 2017, Sydney.
Interviews /
by Jessica Amir -
A year ago
11 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks cancer trials for the company's lead drug candidate, HER-Vaxx, strategy and outlook.
Market Reports /
by -
3 years ago
04 Jan 2016 - Aus shares close 0.48% lower. Amaysim Australia Limited (ASX:AYS) acquires mobile virtual network operator Vaya.
Company News /
by -
3 years ago
20 Apr 2015 - Imugene Limited (ASX:IMU) says leading cancer vaccination is showing a dramatic ten-fold increase in antibodies and has met an additional milestone.
Market Reports /
by -
4 years ago
08 Oct 2014 - ASX follows global selloff. BC Iron Limited (ASX:BCI) increases its relevant interest in Iron Ore Holdings to 90.37%.
